Abstract
Introduction: According to GLOBOCAN estimates, colorectal cancer (CRC) was the third most common cancer worldwide in 2020, comprising 11% of all cancer diagnoses. Researchers’ interest in CRC development has shifted toward the gastrointestinal microbiome, especially the mutagenicity of pks+ E. coli. Therefore, we aimed to review the current evidence on the relationship between pks+ E. coli and CRC. Method: We reviewed the literature reporting the association between pks+ E. coli and CRC, which was obtained from three databases: PubMed, Google Scholar, and the Cochrane Library, published between January 2021 and January 2026. We used the following keywords for our search strategy: pks, Escherichia coli, and colorectal cancer. Result: As stated in the original studies, the contribution of pks+ E. coli to CRC development was associated with a higher prevalence in the CRC group than in the healthy group. However, these results are inconsistent across the studies. Conclusion: Given the limited evidence, researchers should conduct larger cohort studies to clarify this relationship and identify other factors contributing to the presence of pks+ E. coli, particularly across diverse clinical settings. Furthermore, clinical translation, such as the utilization of screening or therapeutic biomarkers, requires prospective validation and standardized detection methods.

This publication has 82 references indexed in Scilit: